Romaguera JE - Search Results

1

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Wang ML, et al. Among authors: romaguera je. N Engl J Med. 2013 Aug 8;369(6):507-16. doi: 10.1056/NEJMoa1306220. Epub 2013 Jun 19. N Engl J Med. 2013. PMID: 23782157 Free PMC article. Clinical Trial.

2

Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma.

Younes A, Sarris A, Melnyk A, Romaguera J, McLaughlin P, Swan F, Rodriguez MA, Hagemeister F, Moore D, North L, et al. Younes A, et al. J Clin Oncol. 1995 Mar;13(3):583-7. doi: 10.1200/JCO.1995.13.3.583. J Clin Oncol. 1995. PMID: 7884419 Clinical Trial.

3

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.

Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F. Velasquez WS, et al. J Clin Oncol. 1994 Jun;12(6):1169-76. doi: 10.1200/JCO.1994.12.6.1169. J Clin Oncol. 1994. PMID: 8201379 Clinical Trial.

4

Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma.

Sarris AH, Younes A, McLaughlin P, Moore D, Hagemeister F, Swan F, Rodriguez MA, Romaguera J, North L, Mansfield P, Callendar D, Mesina O, Cabanillas F. Sarris AH, et al. J Clin Oncol. 1996 Jan;14(1):233-9. doi: 10.1200/JCO.1996.14.1.233. J Clin Oncol. 1996. PMID: 8558203 Clinical Trial.

5

No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule.

Younes A, Ayoub JP, Hagemeister FB, McLaughlin P, Sarris A, Rodriguez MA, Swan F Jr, Romaguera JE, Martin J, Cabanillas F. Younes A, et al. Among authors: romaguera je. J Clin Oncol. 1996 Feb;14(2):543-8. doi: 10.1200/JCO.1996.14.2.543. J Clin Oncol. 1996. PMID: 8636769 Clinical Trial.

6

Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial.

Younes A, Ayoub JP, Sarris A, Hagemeister F, North L, Pate O, McLaughlin P, Rodriguez MA, Romaguera J, Kurzrock R, Preti A, Bachier C, Smith T, Cabanillas F. Younes A, et al. Br J Haematol. 1997 Feb;96(2):328-32. doi: 10.1046/j.1365-2141.1997.d01-2012.x. Br J Haematol. 1997. PMID: 9029021 Free article. Clinical Trial.

7

High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome.

Popat U, Przepiork D, Champlin R, Pugh W, Amin K, Mehra R, Rodriguez J, Giralt S, Romaguera J, Rodriguez A, Preti A, Andersson B, Khouri I, Claxton D, de Lima M, Donato M, Anderlini P, Gajewski J, Cabanillas F, van Besien K. Popat U, et al. J Clin Oncol. 1998 Jan;16(1):63-9. doi: 10.1200/JCO.1998.16.1.63. J Clin Oncol. 1998. PMID: 9440724

8

Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma.

Younes A, Romaguera J, Mesina O, Hagemeister F, Sarris AH, Rodriguez MA, McLaughlin P, Preti HA, Bachier C, Cabanillas F. Younes A, et al. Br J Haematol. 1998 Dec;103(3):678-83. doi: 10.1046/j.1365-2141.1998.01048.x. Br J Haematol. 1998. PMID: 9858216 Free article. Clinical Trial.

9

Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.

Romaguera JE, Hagemeister FB, McLaughlin P, Rodriguez MA, Bachier C, Preti H, Sarris AH, Weber D, Younes A, Cabanillas F. Romaguera JE, et al. Leuk Lymphoma. 1998 Dec;32(1-2):97-106. doi: 10.3109/10428199809059250. Leuk Lymphoma. 1998. PMID: 10037005 Clinical Trial.

10

Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination.

Romaguera JE, Rodriguez MA, Hagemeister FB, McLaughlin P, Rodriguez J, Preti A, Younes A, Sarris AH, Cabanillas F. Romaguera JE, et al. Invest New Drugs. 1999;17(2):187-92. doi: 10.1023/a:1006383503022. Invest New Drugs. 1999. PMID: 10638491 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

234 results

Search Page